ArticleDiabetes, obesity & metabolism2024
Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills.
Article in Diabetes, obesity & metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Disparities in GLP-1RA and SGLT2i Uptake: a Systematic Review and an Equity-First Framework for Cardiovascular-Kidney-Metabolic Care.Current cardiology reports · 2026Pooled it
- Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach.Obesity (Silver Spring, Md.) · 2026Guideline
- Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review.World journal of clinical pediatrics · 2026Review
- Sociodemographic and socioeconomic differences in the use of anti-obesity medications: a register study among 282,307 Finnish adults.International journal of obesity (2005) · 2026Article
- Treating Severe Obesity: A Medical Perspective.Advances in therapy · 2026Review
- A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications.Obesity science & practice · 2026Review
- Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach.Obesity pillars · 2026Article
- Racial and ethnic disparities in GLP-1 prescriptions among veterans with obesity across direct and community care settings.Health affairs scholar · 2026Article
- Disparities in Adolescent and Young Adult Obesity Medication Dispensing: A Retrospective Linked EHR-Pharmacy Cohort, 2020-2025.Obesity (Silver Spring, Md.) · 2026Article
- Healthcare Provider Awareness and Perspectives on Obesity: A Survey Across Medical Specialties.Obesity science & practice · 2026Article
- Trends in Use of Obesity Medications and Metabolic and Bariatric Surgery Among All of Us Participants From 2003 to 2023.Obesity (Silver Spring, Md.) · 2026Article
- Exploring Racial and Ethnic Differences in Utilization of Medications for Obesity Management in a Nationally Representative Survey.Journal of racial and ethnic health disparities · 2026Article
- Beyond glycemic control: Sex differences shaping glucagon-like peptide-1 receptor agonist utilization in the United States.Journal of managed care & specialty pharmacy · 2026Article
- Understanding obesity treatment choices: a mixed-methods study of patient preferences and shared decision-making.Translational behavioral medicine · 2026Article
- Effectiveness of Liraglutide in Patients With Obesity Who Are Early Non-Responders to Lifestyle Intervention: A Real-World Study.Journal of obesity · 2026Observational
- Prescribing GLPs for Obesity Treatment for Adults at a University Based Health Maintenance Organization by Race, Ethnicity, and Socioeconomic Status.Journal of general internal medicine · 2026Article
- GLP-1 receptor agonists in primary care: readiness, equity, and the risk of a two-tiered obesity treatment landscape.Therapeutic advances in endocrinology and metabolism · 2026Review
- Topiramate Enhances GABAergic Tone to Orexigenic Neuropeptide Y/Agouti-Related Peptide (NPY/AgRP) Neurons.Obesity (Silver Spring, Md.) · 2026Article
- Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice.Obesity (Silver Spring, Md.) · 2025Article
- Socio-demographic and clinical factors associated with the receipt of anti-obesity medication prescriptions and metabolic and bariatric surgery among eligible all of Us participants.Diabetes, obesity & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
aimTo characterize factors associated with the receipt of anti-obesity medication (AOM) prescription and fill. MATERIALS AND
methodsThis retrospective cohort study used electronic health records from 1 January 2015 to 30 June 2023, in a large health system in Ohio and Florida. Adults with a body mass index ≥30 kg/m
resultsWe identified 50 678 adults, with a mean body mass index of 38 ± 8 kg/m
conclusionsSignificant disparities exist in access to AOM both at the prescribing stage and getting the prescription filled based on patient characteristics and insurance type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.